Stock listing
OTC:CLPBF Coloplast A/S Stock
US listing (OTC) of Coloplast A/S · home listing Copenhagen:COLOB
Follow Coloplast A/S into a list and get an email when it puts out news.
Share price · OTC:CLPBF
$74.45 USD -0.87 (-1.2%)
Close on Nov 20, 2026
- Day range
- $74.45 – $74.45 USDNov 20, 2026
- Volume
- 32 sharesNov 20, 2026
- Market cap
- $16.78B USDAt the close on Nov 20, 2026 · price × 225.4M shares outstanding

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Xetra:CBHD | €65.86 EUR | -0.66 (-1.0%) | 477 | €67.36 | €67.56 | €65.64 | €66.52 | Close on Nov 20, 2026 |
| OTC:CLPBY | $7.19 USD | -0.09 (-1.2%) | 11,981 | $7.31 | $7.35 | $7.19 | $7.28 | Close on Nov 20, 2026 |
| OTC:CLPBF | $74.45 USD | -0.87 (-1.2%) | 32 | $74.45 | $74.45 | $74.45 | $75.32 | Close on Nov 20, 2026 |
| Frankfurt:CBHD | €66.30 EUR | -0.34 (-0.5%) | — | €66.00 | €66.40 | €66.00 | €66.64 | Close on Nov 20, 2026 |
| Stuttgart:CBHD | €66.08 EUR | 0.00 (0.0%) | 82 | €66.02 | €67.78 | €66.02 | €66.08 | Close on Nov 20, 2026 |
| Frankfurt:CBH | €6.45 EUR | -0.15 (-2.3%) | — | €6.45 | €6.45 | €6.45 | €6.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:CLPBF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $72.70 | 0.00 | 0.0% | $72.70 | $72.70 | $72.70 | 0 | |
| $72.70 | 0.00 | 0.0% | $72.70 | $72.70 | $72.70 | 0 | |
| $72.70 | 0.00 | 0.0% | $72.70 | $72.70 | $72.70 | 0 | |
| $72.70 | +3.44 | +5.0% | $72.70 | $72.70 | $72.70 | 100 | |
| $69.26 | -1.98 | -2.8% | $69.25 | $69.26 | $68.55 | 300 | |
| $71.24 | 0.00 | 0.0% | $71.24 | $71.24 | $71.24 | 0 | |
| $71.24 | +1.22 | +1.7% | $71.24 | $71.24 | $71.24 | 100 | |
| $70.02 | -0.146 | -0.2% | $70.02 | $70.02 | $70.02 | 20 | |
| $70.17 | +8.549 | +13.9% | $70.17 | $70.17 | $70.17 | 45,611 | |
| $61.62 | -1.193 | -1.9% | $61.62 | $61.62 | $61.62 | 350 | |
| $62.81 | +0.51 | +0.8% | $62.81 | $62.81 | $62.81 | 3 | |
| $62.30 | -6.025 | -8.8% | $62.34 | $62.34 | $62.30 | 65 | |
| $68.33 | +2.045 | +3.1% | $68.33 | $68.33 | $68.33 | 39 |
Splits
1 split · OTC:CLPBF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 5-for-1 | Split |
- Ticker
- OTC:CLPBF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Sep 24, 2026
Coloplast A/S - Financial Calendar 2026/27
Latest earnings call · Aug 18, 2026
Coloplast (Copenhagen:COLO B) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 18, 2026
Q3 2026 Earnings Presentation
Earnings · 10 slides
Latest news
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
May 12, 2026
Closed $64.64 (+2.2%) on May 13, 2026
Coloplast Receives Innovative Technology Contract from Vizient for Biatain® Silicone Fit
May 1, 2026
Closed $63.59 (-1.0%) on May 4, 2026
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
Apr 23, 2026
Closed $64.00 (-3.8%) on Apr 28, 2026
Coloplast A/S - H1 2025/26 Earnings Release - Invitation for conference call on 12 May 2026 at 11: 00 CEST
Apr 22, 2026
Closed $66.50 (-3.1%) on Apr 22, 2026
Coloplast appoints Gavin Wood as new CEO
Mar 4, 2026
Closed $72.28 (-2.2%) on Mar 4, 2026
Coloplast A/S - Interim Financial Report, Q1 2025/26
Feb 6, 2026
Closed $80.00 (-5.9%) on Feb 6, 2026
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
Jan 26, 2026
Closed $83.42 (-0.9%) on Jan 26, 2026
Coloplast A/S on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 12 in the last 12 months · 23 in all · newest Sep 24, 2026 · oldest 2025
- Calls
- 11 calls with a replay · 11 with a transcript · latest Aug 18, 2026
- Decks
- 209 decks · latest Aug 18, 2026
Where Coloplast A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:COLOB · Home listing | Copenhagen | Denmark | DKK |
| Xetra:CBHD | Xetra | Germany | EUR |
| LSIN:0QBO | LSIN | United Kingdom | DKK |
| OTC:CLPBY | OTC | United States | USD |
| gettex:CBHD | gettex | Germany | EUR |
| VIE:COLO | Vienna | Austria | EUR |
| Tradegate:CBHD | Tradegate | Germany | EUR |
| OTC:CLPBF · This page | OTC | United States | USD |
| Aquis:COLOBC | Aquis | United Kingdom | DKK |
| Frankfurt:CBHD | Frankfurt | Germany | EUR |
| gettex:CBH | gettex | Germany | EUR |
| LS Exchange:A1KAGC | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1KAGC | Lang & Schwarz | Germany | EUR |
| Stuttgart:CBHD | Stuttgart | Germany | EUR |
| BX Swiss:CBHD | BX Swiss | Switzerland | CHF |
| Turquoise:COLOBC | Turquoise | United Kingdom | DKK |
| Dusseldorf:CBHD | Dusseldorf | Germany | EUR |
| Aquis:COLOBC | Aquis | United Kingdom | DKK |
| BMV:0QBON | BMV | Mexico | MXN |
| Hanover:CBHD | Hanover | Germany | EUR |
| Hamburg:CBHD | Hamburg | Germany | EUR |
| Munich:CBH | Munich | Germany | EUR |
| Munich:CBHD | Munich | Germany | EUR |
| BIVA:0QBON | BIVA | Mexico | MXN |
| Dusseldorf:CBH | Dusseldorf | Germany | EUR |
| Frankfurt:CBH | Frankfurt | Germany | EUR |
Valuation
P/E 33.4× against a median of 40.4×: 5th lowest of 10 Medical devices & supplies companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 123.7B DKK
- P/E
- 33.4×
- EV/sales
- 4.3×
- EV/EBITDA
- 10.5×
- Price/book
- 7.2×
- Gross margin
- 66.5%
- Operating margin
- 25.4%
- Net margin
- 10.6%
- Debt to equity
- 1.5×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Coloplast A/S Class B · OMXCOP:COLO_B | US$15.08B | US$18.16B | 33.4× | 4.3× | 10.5× | 7.2× | 10.6% | 1.5× | n/a |
| Sonova Holding AG · SIX:SOON | US$20.69B | US$21.87B | 40.4× | 5.1× | 19.6× | 6.7× | 11.9% | 0.7× | n/a |
| Straumann Holding AG · SIX:STMN | US$20.27B | US$20.39B | 47.8× | 6.6× | 24.6× | 7.5× | 13.7% | 0.2× | n/a |
| Zimmer Biomet Holdings, Inc. · NYSE:ZBH | US$19.13B | US$26.24B | 24.9× | 3.1× | 11.6× | 1.5× | 8.9% | 0.6× | 0.40 |
| Shanghai United Imaging Healthcare Co., Ltd. Class A · SSE:688271 | US$14.48B | US$13.77B | 54.1× | 5.9× | n/a | 4.4× | 11.5% | 0.1× | n/a |
| Solventum Corporation · NYSE:SOLV | US$14.36B | US$18.98B | 92.1× | 2.3× | 20.0× | 3.0× | 1.9% | 1.1× | 0.56 |
| Baxter International Inc. · NYSE:BAX | US$13.14B | US$12.00B | n/a | 1.0× | 16.2× | 2.0× | −6.2% | 0.1× | 0.97 |
| Penumbra, Inc. · NYSE:PEN | US$12.58B | US$11.90B | 80.1× | 7.6× | n/a | 7.9× | 10.1% | 0.0× | 0.18 |
| Smith & Nephew plc · LSE:SN. | US$12.54B | US$15.58B | 20.1× | 2.5× | 11.4× | 2.4× | 10.1% | 0.7× | n/a |
| The Cooper Companies, Inc. · NASDAQ:COO | US$11.20B | US$13.59B | 19.6× | 3.2× | 14.6× | 1.3× | 13.5% | 0.3× | 0.50 |
| Align Technology, Inc. · NASDAQ:ALGN | US$11.02B | US$9.88B | 22.4× | 2.4× | 11.5× | 2.6× | 11.8% | 0.0× | 1.26 |
| Median of the others | US$13.75B | US$14.68B | 40.4× | 3.1× | 15.4× | 2.8× | 10.8% | 0.3× | 0.53 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 473.81 DKK · Analysts' mean
- EPS, year to Sep 2027
- 24.99 · 20 analysts
- Revenue, year to Sep 2027
- 31.21B · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin Wood | President & CEO of Coloplast |
| Anders Lonning-Skovgaard | Executive Vice President, CFO |
| Julie Sommer Müggler | Coordinator & PA, Investor Relations |
| Kristine Husted Munk | Senior Director, Investor Relations |
| Nicklas Overgaard | Senior Manager, Investor Relations |
| Simone Dyrby Helvind | Sr. Manager, Investor Relations |
| Allan Rasmussen | Executive Vice President, Global Operations |
| Amanda Rajkumar | Executive Vice President, Chief People Officer |
| Caroline Vagner Rosenstand | Executive Vice President, Chronic Care Commercial |
| Kevin Hardage | Executive Vice President, Interventional Urology |
| Rasmus Just | Executive Vice President, Chronic Care R&D |
| Thomas Barfod | Senior Controller and member of the Coloplast Board |
Board
| Director | Role |
|---|---|
| Jette Nygaard-Andersen | Interim Chair of the Board |
Events
- Next results
- Feb 9, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Coloplast (Copenhagen:COLO B) Q3 2026 Earnings Call | Tue, Aug 18, 2026 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2026 Earnings Call | Tue, May 12, 2026 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q1 2026 Earnings Call | Fri, Feb 06, 2026 · 12:00 PM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q4 2025 Earnings Call | Tue, Nov 04, 2025 · 7:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q3 2025 Earnings Call | Tue, Aug 19, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2025 Earnings Call | Tue, May 06, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q1 2025 Earnings Call | Tue, Feb 04, 2025 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q4 2024 Earnings Call | Tue, Nov 05, 2024 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q3 2024 Earnings Call | Tue, Aug 20, 2024 · 5:00 AM ET | Replay |
| Coloplast (Copenhagen:COLO B) Q2 2024 Earnings Call | Tue, May 07, 2024 · 3:00 AM ET | Replay |
All 11 calls
| Call | When | Status |
|---|---|---|
| Coloplast (Copenhagen:COLO B) Q1 2024 Earnings Call | Fri, Feb 09, 2024 · 5:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 3, 2026 · After close | +5.5% |
| Q3 2026 | Aug 18, 2026 · Before open | +3.0% |
| Q2 2026 | May 12, 2026 · Before open | +1.6% |
| Q1 2026 | Feb 6, 2026 · Before open | −8.2% |
| Q4 2025 | Nov 4, 2025 · Before open | +4.8% |
| Q3 2025 | Aug 19, 2025 · Before open | −1.2% |
| Q2 2025 | May 6, 2025 · Before open | −6.0% |
| Q1 2025 | Feb 4, 2025 · Before open | −2.4% |
| Q4 2024 | Nov 5, 2024 · Before open | −0.3% |
| Q3 2024 | Aug 20, 2024 · Before open | −5.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 7, 2024 · Before open | −3.5% |
| Q1 2024 | Feb 9, 2024 · Before open | +9.7% |
| Q4 2023 | Nov 9, 2023 · Before open | −6.9% |
| Q3 2023 | Aug 17, 2023 · Before open | −2.6% |
| Q2 2023 | May 11, 2023 · Before open | −4.3% |
| Q1 2023 | Feb 3, 2023 · Before open | −1.7% |
| Q4 2022 | Nov 7, 2022 · Before open | −2.1% |
| Q3 2022 | Aug 17, 2022 · Before open | +7.3% |
| Q2 2022 | May 5, 2022 · Before open | −5.5% |
| Q1 2022 | Jan 25, 2022 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 10 slides | Aug 18, 2026 |
| 9M 2025/26 Earnings Presentation | Earnings | 99 slides | August 2026 |
| Non-Deal Roadshow (May 2026) | Roadshow | 98 slides | May 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 9 slides | Feb 6, 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 94 slides | February 2026 |
| Q1 2025/26 Earnings Presentation | Earnings | 95 slides | February 2026 |
| Q2 2025/26 Earnings Presentation | Earnings | 4 slides | 2026 |
| Shareholder Meeting (December 2025) | Shareholder meeting | 37 slides | December 2025 |
| FY 2024/25 Earnings Presentation | Earnings | 10 slides | Nov 4, 2025 |
| Non-Deal Roadshow (November 2025) | Roadshow | 97 slides | November 2025 |
Show 50 decks
This page holds 50 of 209 decks. Open Decks
Financials
Annual, in DKK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.9B | 27.9B | 27.0B | 24.5B | 22.6B | 19.4B | 18.5B | 17.9B | 16.4B | 15.5B |
| Cost of revenue | 9.70B | 8.93B | 8.76B | 8.17B | 7.05B | 6.11B | 5.93B | 5.79B | 5.38B | 4.96B |
| Gross profit | 19.2B | 18.9B | 18.3B | 16.3B | 15.5B | 13.3B | 12.6B | 12.2B | 11.1B | 10.6B |
| Research and development | 1.07B | 946.0M | 913.0M | 872.0M | 866.0M | 755.0M | 708.0M | 692.0M | 640.0M | 574.0M |
| Selling, general and administrative | 10.8B | 1.24B | 1.11B | 1.00B | 762.0M | 762.0M | 757.0M | 653.0M | 623.0M | |
| Operating income | 7.36B | 7.20B | 7.32B | 6.77B | 6.44B | 6.36B | 5.85B | 5.16B | 5.09B | 5.02B |
| Depreciation and amortization | 4.43B | 863.0M | 839.0M | 1.07B | 930.0M | 792.0M | 851.0M | 651.0M | 625.0M | 611.0M |
| EBITDA | 11.8B | 8.06B | 8.16B | 7.84B | 7.37B | 7.15B | 6.71B | 5.81B | 5.72B | 5.63B |
| Interest expense | 747.0M | 1.15B | 1.10B | 719.0M | 240.0M | 57.0M | 63.0M | 54.0M | 44.0M | 45.0M |
| Income before tax | 3.85B | 6.16B | 6.39B | 6.03B | 6.13B | 6.23B | 5.47B | 5.03B | 5.01B | 4.95B |
| Income tax | 775.0M | 2.52B | 1.34B | 1.24B | 1.42B | 1.41B | 1.27B | 1.16B | 1.16B | 1.15B |
| Net income | 3.07B | 3.64B | 5.05B | 4.78B | 4.71B | 4.83B | 4.20B | 3.87B | 3.85B | 3.80B |
| Earnings per share, basic | 13.64 | 16.13 | 22.46 | 22.19 | 22.11 | 22.63 | 19.68 | 18.17 | 18.10 | 17.87 |
| Earnings per share, diluted | 16.13 | 22.46 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 511.0M | 947.0M | 788.0M | 911.0M | 414.0M | 448.0M | 323.0M | 356.0M | 297.0M | 314.0M |
| Short-term investments | -39.0M | 219.0M | 226.0M | 262.0M | 313.0M | 310.0M | 315.0M | |||
| Receivables | 5.00B | 4.66B | 4.67B | 4.59B | 4.32B | 3.44B | 3.27B | 3.35B | 3.07B | 3.15B |
| Inventory | 4.06B | 3.92B | 3.67B | 3.52B | 3.19B | 2.43B | 2.23B | 1.93B | 1.73B | 1.69B |
| Current assets | 9.95B | 10.5B | 10.4B | 9.94B | 8.77B | 6.99B | 6.49B | 6.36B | 5.59B | 6.19B |
| Property, plant and equipment | 6.20B | 5.65B | 4.13B | 3.58B | 3.16B | 2.84B | 2.90B | 2.69B | ||
| Goodwill | 16.5B | 19.3B | 19.4B | 20.0B | 11.8B | 2.03B | 1.98B | 2.03B | 1.98B | 1.72B |
| Total assets | 46.3B | 48.4B | 48.1B | 48.2B | 35.0B | 15.8B | 13.5B | 12.7B | 11.8B | 12.1B |
| Accounts payable | 1.70B | 1.32B | 1.52B | 1.29B | 1.24B | 1.04B | 814.0M | 859.0M | 751.0M | 675.0M |
| Current liabilities | 13.5B | 6.50B | 10.2B | 16.3B | 7.34B | 6.31B | 4.98B | 4.94B | 4.71B | 5.42B |
| Long-term debt | 13.6B | 19.4B | 16.6B | 11.6B | 16.4B | 0 | ||||
| Total debt | 21.5B | 22.6B | 22.6B | 19.6B | 18.7B | 2.79B | 1.75B | 1.21B | 1.36B | 1.46B |
| Total liabilities | 32.0B | 32.2B | 30.1B | 30.9B | 26.7B | 7.67B | 6.09B | 5.82B | 5.35B | 6.10B |
| Shareholders' equity | 14.3B | 16.1B | 17.9B | 17.3B | 8.29B | 8.17B | 7.41B | 6.91B | 6.42B | 5.95B |
| Shares outstanding | 225.4M | 225.4M | 224.9M | 215.5M | 212.8M | 213.2M | 213.3M | 213.1M | 212.4M | 212.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8.01B | 6.64B | 2.77B | 4.23B | 5.10B | 5.29B | 4.76B | 4.36B | 4.36B | 3.25B |
| Capital spending | -1.39B | -1.31B | -1.17B | -1.24B | -1.14B | -1.97B | -931.0M | -636.0M | -669.0M | -685.0M |
| Free cash flow | 6.62B | 5.34B | 1.60B | 2.98B | 3.96B | 3.32B | 3.83B | 3.72B | 3.69B | 2.57B |
| Cash from investing | -1.73B | -1.25B | -1.34B | -8.96B | -11.8B | -2.01B | -901.0M | -591.0M | -947.0M | -1.62B |
| Cash from financing | -6.75B | -5.19B | -1.52B | 5.26B | 6.59B | -3.18B | -3.86B | -3.71B | -3.43B | -1.86B |
| Dividends paid | -5.18B | -4.96B | -4.72B | -4.25B | -4.04B | -3.83B | -3.61B | -3.40B | -3.29B | -2.86B |
| Share buybacks | 0 | -619.0M | -500.0M | -500.0M | -500.0M | -500.0M | -500.0M | |||
| Change in cash | -436.0M | 207.0M | -88.0M | 534.0M | -34.0M | 125.0M | -33.0M | 59.0M | -17.0M | -241.0M |
Cap table
Built by 6ix from Coloplast A/S Class B’s releases
- Common shares
- 207,368,138
- Fully diluted
- 207,368,138
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 207,368,138 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 207,368,138 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Allan Rasmussen | Executive Vice President, Global Operations · Since at least Jun 3, 2025 |
| Amanda Rajkumar | Executive Vice President, Chief People Officer · Since at least Nov 5, 2026 |
| Anders Lonning-Skovgaard | Executive Vice President, CFO · Since at least Sep 24, 2026 |
| Caroline Vagner Rosenstand | Executive Vice President, Chronic Care Commercial · Since at least Aug 19, 2025 |
| Gavin Wood | President & CEO of Coloplast · Since May 1, 2026 |
| Jette Nygaard-Andersen | Interim Chair of the Board · Since at least Mar 4, 2026 |
| Julie Sommer Müggler | Coordinator & PA, Investor Relations · Since at least Apr 22, 2026 |
| Kevin Hardage | Executive Vice President, Interventional Urology · Since at least Dec 18, 2025 |
| Kristine Husted Munk | Senior Director, Investor Relations · Since at least Sep 24, 2026 |
| Nicklas Overgaard | Senior Manager, Investor Relations · Since at least Sep 24, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Rasmus Just | Executive Vice President, Chronic Care R&D · Since at least Aug 19, 2025 |
| Simone Dyrby Helvind | Sr. Manager, Investor Relations · Since at least May 12, 2026 |
| Thomas Barfod | Senior Controller and member of the Coloplast Board · Since at least Dec 4, 2025 |
Log in to ask 6ix AI your own questions about Coloplast A/S.